Drug Profile
Mavelertinib - Pfizer
Alternative Names: PF-06747775; PF-7775; PF6747775; PFE-X775Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Purines; Pyrazoles; Pyrrolidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer
Most Recent Events
- 31 Aug 2020 Pfizer terminates a phase II trial in Non-small cell lung cancer (Monotherapy, Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA, Australia, Japan and South Korea, due to strategic reasons and changes in the external environment (NCT02349633)
- 31 Jul 2018 Discontinued - Phase-I/II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Japan, Australia, South Korea, USA (PO)
- 31 Jul 2018 Discontinued - Phase-I/II for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in Australia, Japan, South Korea, USA (PO)